OCM
TEVA icon

One Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

One Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-36,307
Closed -$1.21M – 156
2017
Q2 		$1.21M Buy
36,307
+949
+3% +$29.4K 0.35% 75
2017
Q1 		$1.14M Buy
35,358
+3,389
+11% +$116K 0.35% 75
2016
Q4 		$1.16M Buy
31,969
+1,048
+3% +$41.8K 0.37% 71
2016
Q3 		$1.42M Buy
30,921
+1,511
+5% +$78.8K 0.46% 69
2016
Q2 		$1.48M Buy
29,410
+2,129
+8% +$113K 0.51% 66
2016
Q1 		$1.46K Buy
27,281
+2,479
+10% +$145K 0.06% 66
2015
Q4 		$1.68M Sell
24,802
-621
-2% -$38.4K 0.57% 58
2015
Q3 		$1.44M Sell
25,423
-605
-2% -$39.2K 0.52% 63
2015
Q2 		$1.54M Buy
26,028
+616
+2% +$38K 0.44% 72
2015
Q1 		$1.58M Buy
25,412
+1,482
+6% +$86.2K 0.48% 66
2014
Q4 		$1.38M Buy
23,930
+945
+4% +$52.6K 0.52% 63
2014
Q3 		$1.24M Sell
22,985
-945
-4% -$50.1K 0.44% 66
2014
Q2 		$1.25M Buy
23,930
+143
+0.6% +$7.31K 0.51% 66
2014
Q1 		$1.26M Buy
+23,787
New +$1.1M 0.48% 68

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

One Capital Management's TEVA Position: Q3 2017 in Review

One Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 36,307 shares — an estimated $1.21M sold.

One Capital Management first reported a position in TEVA in Q1 2014 and held it in 14 quarters. The position peaked at $1.68M in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • One Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • One Capital Management sold 36,307 Teva Pharmaceuticals shares in Q3 2017, an estimated $1.21M.
  • One Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 14 quarters.
  • One Capital Management's Teva Pharmaceuticals position peaked at $1.68M in Q4 2015.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on One Capital Management's 13F filing for Q3 2017, filed 2 Nov 2017.